Switch theme
Sign up to access all valuation multiples
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
2017
1K+
LTM Revenue $634M
LTM EBITDA $91.7M
$5.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Telix Pharmaceuticals has a last 12-month revenue (LTM) of $634M and a last 12-month EBITDA of $91.7M.
In the most recent fiscal year, Telix Pharmaceuticals achieved revenue of $503M and an EBITDA of $59.5M.
Telix Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Telix Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $634M | XXX | $503M | XXX | XXX | XXX |
| Gross Profit | $418M | XXX | $327M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $91.7M | XXX | $59.5M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $94.9M | XXX | $52.3M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $66.9M | XXX | $32.1M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Telix Pharmaceuticals's stock price is AUD 26 (or $17).
Telix Pharmaceuticals has current market cap of AUD 8.7B (or $5.6B), and EV of AUD 8.6B (or $5.5B).
See Telix Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.5B | $5.6B | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Telix Pharmaceuticals has market cap of $5.6B and EV of $5.5B.
Telix Pharmaceuticals's trades at 11.0x EV/Revenue multiple, and 93.0x EV/EBITDA.
Equity research analysts estimate Telix Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Telix Pharmaceuticals has a P/E ratio of 83.9x.
See valuation multiples for Telix Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.6B | XXX | $5.6B | XXX | XXX | XXX |
| EV (current) | $5.5B | XXX | $5.5B | XXX | XXX | XXX |
| EV/Revenue | 8.7x | XXX | 11.0x | XXX | XXX | XXX |
| EV/EBITDA | 60.3x | XXX | 93.0x | XXX | XXX | XXX |
| EV/EBIT | 58.3x | XXX | 105.7x | XXX | XXX | XXX |
| EV/Gross Profit | 13.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 83.9x | XXX | 175.0x | XXX | XXX | XXX |
| EV/FCF | -218.5x | XXX | 956.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTelix Pharmaceuticals's last 12 month revenue growth is 44%
Telix Pharmaceuticals's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Telix Pharmaceuticals's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Telix Pharmaceuticals's rule of X is 126% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Telix Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 44% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 73% | XXX | 235% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 56% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 126% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Telix Pharmaceuticals acquired XXX companies to date.
Last acquisition by Telix Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Telix Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Telix Pharmaceuticals founded? | Telix Pharmaceuticals was founded in 2017. |
| Where is Telix Pharmaceuticals headquartered? | Telix Pharmaceuticals is headquartered in Australia. |
| How many employees does Telix Pharmaceuticals have? | As of today, Telix Pharmaceuticals has 1K+ employees. |
| Who is the CEO of Telix Pharmaceuticals? | Telix Pharmaceuticals's CEO is Dr. Christian Behrenbruch, D.Phil.,J.D.. |
| Is Telix Pharmaceuticals publicy listed? | Yes, Telix Pharmaceuticals is a public company listed on ASX. |
| What is the stock symbol of Telix Pharmaceuticals? | Telix Pharmaceuticals trades under TLX ticker. |
| When did Telix Pharmaceuticals go public? | Telix Pharmaceuticals went public in 2017. |
| Who are competitors of Telix Pharmaceuticals? | Similar companies to Telix Pharmaceuticals include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Telix Pharmaceuticals? | Telix Pharmaceuticals's current market cap is $5.6B |
| What is the current revenue of Telix Pharmaceuticals? | Telix Pharmaceuticals's last 12 months revenue is $634M. |
| What is the current revenue growth of Telix Pharmaceuticals? | Telix Pharmaceuticals revenue growth (NTM/LTM) is 44%. |
| What is the current EV/Revenue multiple of Telix Pharmaceuticals? | Current revenue multiple of Telix Pharmaceuticals is 8.7x. |
| Is Telix Pharmaceuticals profitable? | Yes, Telix Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Telix Pharmaceuticals? | Telix Pharmaceuticals's last 12 months EBITDA is $91.7M. |
| What is Telix Pharmaceuticals's EBITDA margin? | Telix Pharmaceuticals's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Telix Pharmaceuticals? | Current EBITDA multiple of Telix Pharmaceuticals is 60.3x. |
| What is the current FCF of Telix Pharmaceuticals? | Telix Pharmaceuticals's last 12 months FCF is -$25.3M. |
| What is Telix Pharmaceuticals's FCF margin? | Telix Pharmaceuticals's last 12 months FCF margin is -4%. |
| What is the current EV/FCF multiple of Telix Pharmaceuticals? | Current FCF multiple of Telix Pharmaceuticals is -218.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
